Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Recent Advances in Pharmaceutical Dosage Forms
share announcement

Recent Advances in Pharmaceutical Dosage Forms

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: 20 July 2024 | Viewed by 2935

Special Issue Editors

Prof. Dr. Juan José Torrado Durán

E-Mail Website
Guest Editor
Pharmaceutics and Food Technology, School of Pharmacy, Complutense University of Madrid, Madrid, Spain
Interests: conventional pharmaceutical dosage forms (tablets, capsules, semisolid and liquid formulations); new controlled release systems (pellets, nanoparticles, microcapsules, microspheres and liposomes) including production and quality control
Special Issues, Collections and Topics in MDPI journals
Dr. Dolores R. Serrano

E-Mail Website1 Website2
Guest Editor
Departament of Pharmaceutics and Food Technology, School of Pharmacy, University Complutense, Avenida Complutense, 28040 Madrid, Spain
Interests: nanomedicines; microparticles; sustained-release formulations; liposomes; nanoparticles; drug targeting; pharmacokinetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Active pharmaceutical ingredients have to be formulated in the most suitable dosage form according to the administration route. Suitable drug delivery is obtained through careful excipient selection and fabrication. Current advances in the development of novel drug dosage forms focus on the use of new excipients, innovative technologies, and better knowledge and control of pharmaceutical manufacturing processes. This Special Issue deals with the following items related to pharmaceutical dosage forms:

  • Dosage form optimization design based on DOE and multivariable analysis.
  • Use and application of novel excipients.
  • Innovation in drug formulation and characterization techniques.
  • Improvements in process quality control.
  • Continuous manufacturing.
  • Process analytical technology applied to drug manufacturing.
  • 2D and 3D printing technologies.

Prof. Dr. Juan José Torrado Durán
Dr. Dolores R. Serrano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • excipient
  • formulation
  • drug
  • quality
  • design
  • dosage form
  • drug delivery
  • 3D printing

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

25 pages, 7465 KiB  
Article
Design and Characterization of Ocular Inserts Loaded with Dexamethasone for the Treatment of Inflammatory Ophthalmic Disease
by Omar Rodrigo Guadarrama-Escobar, Cassandra Araceli Valdés-Alvarez, Karla Stella Constantino-Gonzalez, Pablo Serrano-Castañeda, Ma. Concepción Peña-Juárez, Miriam Isabel Morales-Florido, Mariana Salgado-Machuca, Betsabe Rodríguez-Pérez, Isabel Marlen Rodriguez-Cruz, Dinorah Vargas-Estrada, Crisóforo Mercado-Márquez, Alma Vázquez-Durán, Abraham Méndez-Albores, Ericka Anguíano-Almazán and José Juan Escobar-Chavez
Pharmaceutics 2024, 16(2), 294; https://doi.org/10.3390/pharmaceutics16020294 - 19 Feb 2024
Viewed by 953
Abstract
The short precorneal residence time of ophthalmic drops is associated with their low absorption; therefore, the development of ocular inserts capable of prolonging and controlling the ophthalmic release of drugs is an interesting option in the design and development of these drugs. A [...] Read more.
The short precorneal residence time of ophthalmic drops is associated with their low absorption; therefore, the development of ocular inserts capable of prolonging and controlling the ophthalmic release of drugs is an interesting option in the design and development of these drugs. A surface response design was developed, specifically the Central Composite Design (CCD), to produce ophthalmic films loaded with Dexamethasone (DEX) by the solvent evaporation method having experimental levels of different concentrations of previously selected polymers (PVP K-30 and Eudragit RS100.). Once optimization of the formulation was obtained, the in vivo test was continued. The optimal formulation obtained a thickness of 0.265 ± 0.095 mm, pH of 7.11 ± 0.04, tensile strength of 15.50 ± 3.94 gF, humidity (%) of 22.54 ± 1.7, mucoadhesion strength of 16.89 ± 3.46 gF, chemical content (%) of 98.19 ± 1.124, release of (%) 13,510.71, and swelling of 0.0403 ± 0.023 g; furthermore, in the in vivo testing the number and residence time of PMN cells were lower compared to the Ophthalmic Drops. The present study confirms the potential use of polymeric systems using PVPK30 and ERS100 as a new strategy of controlled release of ophthalmic drugs by controlling and prolonging the release of DEX at the affected site by decreasing the systemic effects of the drug. Full article
(This article belongs to the Special Issue Recent Advances in Pharmaceutical Dosage Forms)
►▼ Show Figures

Figure 1

17 pages, 12694 KiB  
Article
Co-Delivery of a High Dose of Amphotericin B and Itraconazole by Means of a Dry Powder Inhaler Formulation for the Treatment of Severe Fungal Pulmonary Infections
by Salomé S. Celi, Raquel Fernández-García, Andreina I. Afonso-Urich, M. Paloma Ballesteros, Anne Marie Healy and Dolores R. Serrano
Pharmaceutics 2023, 15(11), 2601; https://doi.org/10.3390/pharmaceutics15112601 - 08 Nov 2023
Cited by 2 | Viewed by 922
Abstract
Over the past few decades, there has been a considerable rise in the incidence and prevalence of pulmonary fungal infections, creating a global health problem due to a lack of antifungal therapies specifically designed for pulmonary administration. Amphotericin B (AmB) and itraconazole (ITR) [...] Read more.
Over the past few decades, there has been a considerable rise in the incidence and prevalence of pulmonary fungal infections, creating a global health problem due to a lack of antifungal therapies specifically designed for pulmonary administration. Amphotericin B (AmB) and itraconazole (ITR) are two antifungal drugs with different mechanisms of action that have been widely employed in antimycotic therapy. In this work, microparticles containing a high dose of AmB and ITR (20, 30, and 40% total antifungal drug loading) were engineered for use in dry powder inhalers (DPIs) with an aim to improve the pharmacological effect, thereby enhancing the existing off-label choices for pulmonary administration. A Design of Experiment (DoE) approach was employed to prepare DPI formulations consisting of AmB-ITR encapsulated within γ-cyclodextrin (γ-CD) alongside functional excipients, such as mannitol and leucine. In vitro deposition indicated a favourable lung deposition pattern characterised by an upper ITR distribution (mass median aerodynamic diameter (MMAD) ~ 6 µm) along with a lower AmB deposition (MMAD ~ 3 µm). This offers significant advantages for treating fungal infections, not only in the lung parenchyma but also in the upper respiratory tract, considering that Aspergillus spp. can cause upper and lower airway disorders. The in vitro deposition profile of ITR and larger MMAD was related to the higher unencapsulated crystalline fraction of the drug, which may be altered using a higher concentration of γ-CD. Full article
(This article belongs to the Special Issue Recent Advances in Pharmaceutical Dosage Forms)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop